TY - JOUR
T1 - Exon resequencing of H3K9 methyltransferase complex genes, EHMT1, EHTM2 and WIZ, in Japanese autism subjects
AU - Balan, Shabeesh
AU - Iwayama, Yoshimi
AU - Maekawa, Motoko
AU - Toyota, Tomoko
AU - Ohnishi, Tetsuo
AU - Toyoshima, Manabu
AU - Shimamoto, Chie
AU - Esaki, Kayoko
AU - Yamada, Kazuo
AU - Iwata, Yasuhide
AU - Suzuki, Katsuaki
AU - Ide, Masayuki
AU - Ota, Motonori
AU - Fukuchi, Satoshi
AU - Tsujii, Masatsugu
AU - Mori, Norio
AU - Shinkai, Yoichi
AU - Yoshikawa, Takeo
N1 - Funding Information:
This study was supported in part by Grant-in-Aid for Scientific Research on Innovative Areas (TY) from the Japan Society for the Promotion of Science (JSPS), Japan, and by CREST (Core Research for Evolutionary Science and Technology) (YS and TY) from the Japan Science and Technology Agency (JST), Japan. In addition, this study was supported by RIKEN Brain Science Institute Funds (TY). Sections of this study was conducted as part of the ‘Development of biomarker candidates for social behavior’ (TY) and ‘Integrated research on neuropsychiatric disorders’ (NM) projects, carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan. A part of this work was also supported by a grant ‘Platform for Drug Discovery, Informatics, and Structural Life Science’ (MO and SF) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Funding Information:
This study was supported in part by Grant-in-Aid for Scientific Research on Innovative Areas (TY) from the Japan Society for the Promotion of Science (JSPS), Japan, and by CREST (Core Research for Evolutionary Science and Technology) (YS and TY) from the Japan Science and Technology Agency (JST), Japan. In addition, this study was supported by RIKEN Brain Science Institute Funds (TY). Sections of this study was conducted as part of the Development of biomarker candidates for social behavior (TY) and Integrated research on neuropsychiatric disorders (NM) projects, carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan. A part of this work was also supported by a grant Platform for Drug Discovery, Informatics, and Structural Life Science (MO and SF) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Publisher Copyright:
© 2014 Balan et al.
PY - 2014
Y1 - 2014
N2 - Background: Histone H3 methylation at lysine 9 (H3K9) is a conserved epigenetic signal, mediating heterochromati formation by trimethylation, and transcriptional silencing by dimethylation. Defective GLP (Ehmt1) and G9a (Ehmt2 histone lysine methyltransferases, involved in mono and dimethylation of H3K9, confer autistic phenotypes an behavioral abnormalities in animal models. Moreover, EHMT1 loss of function results in Kleefstra syndrome, characterize by severe intellectual disability, developmental delays and psychiatric disorders. We examined the possible role o histone methyltransferases in the etiology of autism spectrum disorders (ASD) and suggest that rare functional variant in these genes that regulate H3K9 methylation may be associated with ASD Methods: Since G9a-GLP-Wiz forms a heteromeric methyltransferase complex, all the protein-coding regions an exon/intron boundaries of EHMT1, EHMT2 and WIZ were sequenced in Japanese ASD subjects. The detected variant were prioritized based on novelty and functionality. The expression levels of these genes were tested in blood cell and postmortem brain samples from ASD and control subjects. Expression of EHMT1 and EHMT2 isoforms wer determined by digital PCR Results: We identified six nonsynonymous variants: Three in EHMT1, two in EHMT2 and one in WIZ. Two variants, th EHMT1 ankyrin repeat domain (Lys968Arg) and EHMT2 SET domain (Thr961Ile) variants were present exclusively in cases but showed no statistically significant association with ASD. The EHMT2 transcript expression was significantly elevated i the peripheral blood cells of ASD when compared with control samples; but not for EHMT1 and WIZ. Gene expressio levels of EHMT1, EHMT2 and WIZ in Brodmann area (BA) 9, BA21, BA40 and the dorsal raphe nucleus (DoRN) region from postmortem brain samples showed no significant changes between ASD and control subjects. Nor did expressio levels of EHMT1 and EHMT2 isoforms in the prefrontal cortex differ significantly between ASD and control groups Conclusions: We identified two novel rare missense variants in the EHMT1 and EHMT2 genes of ASD patients. W surmise that these variants alone may not be sufficient to exert a significant effect on ASD pathogenesis. The elevate expression of EHMT2 in the peripheral blood cells may support the notion of a restrictive chromatin state in ASD, similar to schizophrenia.
AB - Background: Histone H3 methylation at lysine 9 (H3K9) is a conserved epigenetic signal, mediating heterochromati formation by trimethylation, and transcriptional silencing by dimethylation. Defective GLP (Ehmt1) and G9a (Ehmt2 histone lysine methyltransferases, involved in mono and dimethylation of H3K9, confer autistic phenotypes an behavioral abnormalities in animal models. Moreover, EHMT1 loss of function results in Kleefstra syndrome, characterize by severe intellectual disability, developmental delays and psychiatric disorders. We examined the possible role o histone methyltransferases in the etiology of autism spectrum disorders (ASD) and suggest that rare functional variant in these genes that regulate H3K9 methylation may be associated with ASD Methods: Since G9a-GLP-Wiz forms a heteromeric methyltransferase complex, all the protein-coding regions an exon/intron boundaries of EHMT1, EHMT2 and WIZ were sequenced in Japanese ASD subjects. The detected variant were prioritized based on novelty and functionality. The expression levels of these genes were tested in blood cell and postmortem brain samples from ASD and control subjects. Expression of EHMT1 and EHMT2 isoforms wer determined by digital PCR Results: We identified six nonsynonymous variants: Three in EHMT1, two in EHMT2 and one in WIZ. Two variants, th EHMT1 ankyrin repeat domain (Lys968Arg) and EHMT2 SET domain (Thr961Ile) variants were present exclusively in cases but showed no statistically significant association with ASD. The EHMT2 transcript expression was significantly elevated i the peripheral blood cells of ASD when compared with control samples; but not for EHMT1 and WIZ. Gene expressio levels of EHMT1, EHMT2 and WIZ in Brodmann area (BA) 9, BA21, BA40 and the dorsal raphe nucleus (DoRN) region from postmortem brain samples showed no significant changes between ASD and control subjects. Nor did expressio levels of EHMT1 and EHMT2 isoforms in the prefrontal cortex differ significantly between ASD and control groups Conclusions: We identified two novel rare missense variants in the EHMT1 and EHMT2 genes of ASD patients. W surmise that these variants alone may not be sufficient to exert a significant effect on ASD pathogenesis. The elevate expression of EHMT2 in the peripheral blood cells may support the notion of a restrictive chromatin state in ASD, similar to schizophrenia.
KW - Autism
KW - G9a
KW - GLP
KW - H3K
KW - Histone methyltransferase
KW - Rare variant
KW - Wiz
UR - http://www.scopus.com/inward/record.url?scp=84989184528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989184528&partnerID=8YFLogxK
U2 - 10.1186/2040-2392-5-49
DO - 10.1186/2040-2392-5-49
M3 - Article
AN - SCOPUS:84989184528
SN - 2040-2392
VL - 5
JO - Molecular Autism
JF - Molecular Autism
IS - 1
M1 - 49
ER -